| Number of patients |
---|---|
Characteristics | nâ=â159 (%) |
Stage at diagnosis | |
âI | 17 (11) |
âII | 50 (31) |
âIII | 32 (20) |
âIV | 31 (20) |
âUnknown | 28 (17) |
Subtype | |
âHR+ HER2- | 108 (68) |
âHR+ HER2+ | 20 (13) |
âHR- HER2+ | 9 (6) |
âHR- HER2- | 14 (9) |
âUnknown | 8 (5) |
Perioperative chemotherapy | |
âYes | 61 (38) |
âAnthracycline regimen | 11 (7) |
âAnthracycline + taxane regimen | 26 (16) |
âOther regimens | 24 (15) |
âNo | 97 (61) |
âUnknown | 1 (1) |
Adjuvant endocrine therapy | |
âAromatase inhibitor | 39 (25) |
âTamoxifen | 29 (19) |
âOvarian function suppression | 22 (14) |
âNone | 22 (14) |
âUnknown | 1 (1) |
Prior treatment with zoledronic acid | |
âYes | 39 (25) |
âNo | 92 (60) |
âUnknown | 23 (15) |
Number of denosumab doses | median 18 (range: 1â79) |
More than 45 doses of denosumab | 15 (9) |